Kawasaki Disease

Video Blogs
Kawasaki Disease Related to Covid-19 Subscribe Now Considerable confusion surrounds a recently recognized complication of Covid-19 in young children and adolescents.  Since its original description in April 2020 it has been variously referred to as Kawasaki Disease, Toxic Shock Syndrome and Cytokine Storm. More recently the name has been changed from Pediatric Inflammatory Multisystem Syndrome to Multisystem Inflammatory Syndrome in Children. Without Symptoms of Covid-19 Children generally remain free of symptoms during their infection with the coronavirus.  Signs and symptoms of Kawasaki Disease typically manifest in the convalescent phase several weeks after the infection resolves.  It appears the immune system once stimulated to control the virus continues to spiral out of control and attacks tissues throughout the body. https://youtu.be/rguZShGIPqM Kawasaki Disease from WellNowDoctor on YouTube Manifestations Children with Kawasaki Disease…
Read More

Singulair – Not Very Effective

Video Blogs
Subscribe Now Although Singulair or montelukast remains among the most frequently prescribed medicines with more than 25 million prescriptions each year, the drug is not very effective.  It routinely fails to live up to expectations.  Typically employed to treat nasal allergies, rhinitis or hay fever it may be administered to prevent asthma or breathing disorders associated with exercise.  Some doctors also prescribe Singulair off-label for individuals suffering from hives, itchy skin and for wheezing episodes in children.        Dose The dose remains one tablet daily in the evening except when used to prevent exercise related asthma.  These individuals should take the pill two hours before planned activities but the limit remains only one pill within any 24 hour period.  Montelukast is available for children over age 6 months as a packet…
Read More

Remdesivir Treats Covid-19

Video Blogs
Accumulating evidence suggests enthusiasm surrounding Remdesivir as a treatment for Covid-19 appears warranted.  Originally introduced as a treatment during the Ebola epidemic of 2013-2016, Remdesivir targeted the virus in laboratory studies and test animals.  However it offered only mediocre results in comparison to other drugs in a major trial sponsored by the WHO. During initial studies in conjunction with investigators from the CDC, NIAID and US Army Research Institute of Infectious Diseases, Remdesivir demonstrated significant activity against the coronavirus cause of the Middle East Respiratory Syndrome or MERS.  Due to the small number of patients and the restricted geographic area, human testing was not undertaken.  Not unexpectedly laboratory experiments of Remdesivir also revealed enhanced control of the related coronavirus resulting in Severe Acute Respiratory Syndrome or SARS.   Ebola Shortly after…
Read More

Hydroxychloroquine | Maybe For Coronavirus?

Video Blogs
Hydroxychloroquine Although hydyroxchloroquine received FDA marketing approval about 65 years ago, until recently it generated little interest.  Primarily indicated as therapy for systemic lupus erythematosus and rheumatoid arthritis, hydroxychloroquine remains among the top 150 prescription drugs in America.  In some circumstances hydroxychloroquine may also find use in treating or preventing malaria.  Hydroxychloroquine is a close relative of the slightly more toxic chloroquine. Laboratory Studies During the mid-1990s studies in the laboratory, not in humans, demonstrated hydroxychloroquine could inhibit growth of a wide array of RNA viruses including the causative agents of rabies, influenza, Dengue fever and some forms of hepatitis.  Other experiments suggested similar actions against bacteria and fungi.  In 2009 scientists observed an otherwise lethal exposure of newborn mice to coronavirus OC43 could be transformed into a survivable condition…
Read More